ReviewRheumatic diseases clinics of North America2018
Gastrointestinal and Hepatic Disease in Systemic Sclerosis.
Review in Rheumatic diseases clinics of North America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Small Intestinal Bacterial Overgrowth Complicating Gastrointestinal Manifestations of Systemic Sclerosis: A Systematic Review and Meta-analysis.Journal of neurogastroenterology and motility · 2023Pooled it
- Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review and meta-analysis.Clinical rheumatology · 2021Pooled it
- Transdermal Delivery of Hyaluronate-Conjugated Formyl Peptide Receptor 2 Agonistic Peptide Ameliorates Bleomycin-Induced Skin Fibrosis.Biomaterials research · 2026Article
- Criteria for defining and dating onset of organ system involvement in systemic sclerosis.Journal of scleroderma and related disorders · 2025Article
- Light Chain (AL) Amyloidosis Masquerading as Scleroderma: A Diagnostic Challenge.Journal of hematology · 2025Article
- Controlling nutritional status score as a sensitive instrument for malnutrition screening in systemic sclerosis - a retrospective study.Rheumatology international · 2025Article
- Association of nutritional status indices with gastrointestinal symptoms in systemic sclerosis: a cross-sectional study.Rheumatology international · 2025Article
- Review
- Safety of prolonged use of metoclopramide and domperidone as treatment for chronic gastrointestinal dysmotility disorders in patients with systemic sclerosis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- A Multidisciplinary Approach as a Goal for the Management of Complications in Systemic Scleroderma: A Literature Review and Case Scenario.Diagnostics (Basel, Switzerland) · 2023Review
- Article
- The Involvement of Smooth Muscle, Striated Muscle, and the Myocardium in Scleroderma: A Review.International journal of molecular sciences · 2022Review
- Epidemiology and Treatment of Systemic Sclerosis in Korea.Journal of rheumatic diseases · 2022Review
- Treatment of Fingernail Onychomycosis with Efinaconazole 10% Solution in a Patient with Scleroderma: A Case Report.Skin appendage disorders · 2022Article
- Characteristics and Treatment Outcomes of Small-bowel Angioectasia in Systemic Sclerosis Patients: A Retrospective Observational Study.Internal medicine (Tokyo, Japan) · 2022Observational
- Gut microbiome in systemic sclerosis: a potential therapeutic target.Postepy dermatologii i alergologii · 2022Article
- Diet in Scleroderma: Is There a Need for Intervention?Diagnostics (Basel, Switzerland) · 2021Article
- Reliability and validity of the Korean version of the University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis.The Korean journal of internal medicine · 2021Article
- Capsule endoscopy findings reflect the gastrointestinal conditions of patients with systemic sclerosis.Scientific reports · 2021Article
- Dysphagia, reflux and related sequelae due to altered physiology in scleroderma.World journal of gastroenterology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Although classification criteria for systemic sclerosis (SSc) do not incorporate gastrointestinal tract (GIT) manifestations often present in this disease, the GIT is the most common internal organ involved. Pathophysiology of GIT involvement is thought to be similar to other organs in SSc with fibroproliferative vascular lesions of small arteries and arterioles, increased production of profibrotic growth factors, and alterations of innate, humoral, and cellular immunity. These processes result in neuropathy progressing to myopathy with eventual fibrosis. Proper diagnostics and therapeutics for SSc-GIT involvement require the treating physician to have an understanding of an integrated approach and potential medication adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.